Wayne Goodman

Wayne Goodman is an American psychiatrist and researcher who specializes in Obsessive-Compulsive Disorder (OCD). He is the principal developer, along with his colleagues, of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).[1]

Wayne Goodman
American psychiatrist and researcher
Alma materColumbia University
Boston University School of Medicine
Yale School of Medicine
Known forObsessive Compulsive Disorder, Yale-Brown Obsessive Compulsive Scale International OCD Foundation, Deep Brain Stimulation
Scientific career
FieldsPsychiatry, Neurology
InstitutionsBaylor College of Medicine, Icahn School of Medicine at Mount Sinai

In 2016, Goodman was appointed the D.C and Irene Ellwood Professor and chair of the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine. He is also an adjunct professor in the Department of Electrical and Computer Engineering at Rice University.[2]

Biography

Prior to joining Baylor, Goodman was professor and chairman of the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai and The Mount Sinai Behavioral Health System for seven years. During his tenure, the department rose to be among the top ten in the nation in research funding from the National Institutes of Health.[3][4]

Goodman also served as director of the Division of Adult Translational Research and Treatment Development at the National Institute of Mental Health from 2007 to 2009. He was chairman of the Department of Psychiatry at the University of Florida in Gainesville for nine years.

A native of New York City, Goodman attended the Bronx High School of Science and graduated from Columbia University with a degree in electrical engineering. He received his medical degree from Boston University School of Medicine and completed his internship, residency, and research fellowship at Yale School of Medicine.[5]

Major accomplishments in OCD

Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

In 1985, Goodman founded and served as chief of the OCD Clinic at Yale University. During this time, along with his colleagues Lawrence Price and Steven Rasmussen, he developed the Y-BOCS, which is widely used in research and clinical practice to determine the severity of OCD and to monitor improvement during treatment. It has since been translated into numerous languages.[1]

Goodman and his colleagues have also developed the Yale-Brown Obsessive-Compulsive Scale—Second Edition (Y-BOCS-II) in an effort to modify the original scale.[6] Other rating scales developed by Goodman and his colleagues include: the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS),[7] Florida Obsessive Compulsive Inventory (FOCI),[8] the Children's Florida Obsessive Compulsive Inventory (C-FOCI),[9] Level 2—Repetitive Thoughts and Behaviors (Cross-cutting symptom measure used in the DSM-5),[10] and the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP).[11]

Selective serotonin reuptake inhibitors

Goodman was one of the first investigators to test and establish the efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs) in OCD and show their comparative advantage over other antidepressant medications.[12] He also developed the use of adjunctive antipsychotic medications in SSRI-resistant OCD and found that patients with comorbid tic disorders are most likely to respond to this combination.[13]

International OCD Foundation

In 1986, Goodman co-founded the nonprofit OCD Foundation (now named the International OCD Foundation). While on faculty at Yale University, he had the idea to bring together a group of dedicated individuals with OCD who were participating in research studies for a self-help group. They later expanded and started a foundation to help reach a wider audience and educate the public about OCD and treatment options.[14] He served as chair of its scientific advisory board for the first ten years. Goodman received the Lifetime Career Achievement Award from the International OCD Foundation in 2012.[15]

Deep brain stimulation

Goodman conducts research in the use of Deep Brain Stimulation (DBS) for treatment-resistant psychiatric disorders. He has published on the use of DBS for intractable OCD.[16][17] In October 2016, The National Institute of Neurological Disorders and Stroke awarded him a grant for research aimed at developing a new generation of DBS technology. The funding, which was re-issued by the NIH for 2017, is part of President Obama's Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative.[18][19]

Service with the Food and Drug Administration

Goodman served as chair of the FDA Psychopharmacology Drug Advisory Committee (PDAC) from 2004 to 2008. During that time period, the FDA deliberated and eventually decided to require a Black Box warning on suicidality for all antidepressant drugs.[20] Goodman voted in favor of the Black Box warning for the pediatric population in 2004.[21] Two years later, he voted that the warning be extended up to age 24. He has also served on the FDA Neurological Devices Advisory Committee.[22]

References
  1. Goodman, W.K; Price, L.H; Rasmussen, S.A; et al. (1989). "The Yale–Brown Obsessive–Compulsive Scale. I. Development, use, and reliability". Arch Gen Psychiatry. 46 (11): 1006–1011. doi:10.1001/archpsyc.1989.01810110048007. PMID 2684084.
  2. "Goodman named chair of psychiatry and behavioral sciences at Baylor College of Medicine". BCM. 28 Jul 2016.
  3. "Wayne K. Goodman, MD, Renowned Expert on Obsessive Compulsive Disorder, Joins Mount Sinai as Chair of Psychiatry". PRWeb. 4 May 2009.
  4. "Ranking Tables of National Institutes of Health (NIH) Award Data 2014". brimr.org.
  5. "Wayne Goodman - The Mount Sinai Hospital". The Mount Sinai Hospital. Archived from the original on 2016-08-27. Retrieved 2015-07-29.
  6. Storch EA1, Rasmussen SA; Price, LH; Larson, MJ; Murphy, TK; Goodman, WK (Jun 2010). "Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition". Psychol Assess. 22 (2): 223–32. doi:10.1037/a0018492. PMID 20528050.
  7. Scahill, L; Riddle, MA; McSwiggin-Hardin, M; Ort, SI; King, RA; Goodman, WK; Cicchetti, D; Leckman, JF (Jun 1997). "Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity". J Am Acad Child Adolesc Psychiatry. 36 (6): 844–52. doi:10.1097/00004583-199706000-00023. PMID 9183141.
  8. Storch, EA; Kaufman, DA; Bagner, D; Merlo, LJ; Shapira, NA; Geffken, GR; Murphy, TK; Goodman, WK (Sep 2007). "Florida Obsessive-Compulsive Inventory: development, reliability, and validity". J Clin Psychol. 63 (9): 851–9. doi:10.1002/jclp.20382. PMID 17674398.
  9. Storch EA1, Khanna M; Merlo, LJ; Loew, BA; Franklin, M; Reid, JM; Goodman, WK; Murphy, TK (Sep 2009). "Children's Florida Obsessive Compulsive Inventory: psychometric properties and feasibility of a self-report measure of obsessive-compulsive symptoms in youth". Child Psychiatry Hum Dev. 40 (3): 467–83. doi:10.1007/s10578-009-0138-9. PMID 19326209. S2CID 17195058.
  10. American Psychiatric Association.(2013).Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC.
  11. Bussing R, Murphy TK, Storch EA, McNamara JP, Reid AM, Garvan CW, Goodman WK (2013). "Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD". Psychiatry Res. 205 (3): 253–61. doi:10.1016/j.psychres.2012.09.019. PMC 3540123. PMID 23031804.
  12. Goodman, WK; Price, LH; Delgado, PL; Palumbo, J; Krystal, JH; Nagy, LM; Rasmussen, SA; Heninger, GR; Charney, DS (Jun 1990). "Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine". Arch Gen Psychiatry. 47 (6): 577–85. doi:10.1001/archpsyc.1990.01810180077011. PMID 2112374.
  13. McDougle CJ1, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr;51(4):302-8. PBMI 8161290
  14. "History of the Clinic". yale.edu.
  15. "Wayne Goodman, MD, Receives Career Achievement Award from International OCD Foundation". The Mount Sinai Hospital. Archived from the original on 2017-08-02. Retrieved 2015-07-29.
  16. Goodman, WK; Alterman, RL (2012). "Deep brain stimulation for intractable psychiatric disorders". Annu Rev Med. 63: 511–24. doi:10.1146/annurev-med-052209-100401. PMID 22034866.
  17. Goodman, WK; Foote, KD; Greenberg, BD; Ricciuti, N; Bauer, R; Ward, H; Shapira, NA; Wu, SS; Hill, CL; Rasmussen, SA; Okun, MS (Mar 2010). "Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design". Biol Psychiatry. 67 (6): 535–42. doi:10.1016/j.biopsych.2009.11.028. PMC 5796545. PMID 20116047.
  18. "Baylor College of Medicine researcher and collaborators awarded grant through NIH BRAIN Initiative". BCM.
  19. "Funded Awards". NIH.
  20. Goodman WK1, Murphy TK; Storch, EA (Mar 2007). "Risk of adverse behavioral effects with pediatric use of antidepressants". Psychopharmacology. 191 (1): 87–96. doi:10.1007/s00213-006-0642-6. PMID 17180618. S2CID 21055530.
  21. "Food and Drug Administration". fda.gov.
  22. "Archived copy" (PDF). Food and Drug Administration. Archived from the original (PDF) on 2017-05-09. Retrieved 2019-12-16.{{cite web}}: CS1 maint: archived copy as title (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.